MedTrace Logo

Pilot Testing A Theory-Driven Self-Management Intervention for Chronic Musculoskeletal Pain

NCT05020470 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-06-12

No results posted yet for this study

Summary

The proposed randomized control trial will evaluate auricular point acupressure (APA) treatment administered by the participant themselves with the use of a phone app on chronic musculoskeletal pain (CMP) outcomes.

This study will randomly assign participants into three groups: (1) Self-guided mAPA (S-mAPA), (2) In-Person Training + mAPA (IP-mAPA), and (3) Usual Care Control (UC). EMA will be used to assess momentary pain outcomes and APA adherence.

Data will be collected at pre- (T1), post-completion of intervention (T2), follow-ups at post 1M- (primary endpoint) (T3), 2M (T4), and 3M (secondary endpoint, long-term sustained effect) (T5) for a total of four assessments.

Conditions

  • Chronic Musculoskeletal Pain

Interventions

DEVICE

Virtual Auricular Point Acupressure (APA)

Participants will learn how to self-administer APA by themselves.

OTHER

In-Person Training

Participants will receive in-person training to self-administer APA.

OTHER

Usual Care

Participants will continue to do whatever they are instructed by theirs physicians.

Sponsors & Collaborators

Principal Investigators

  • Chao Hsing Yeh, PhD · Johns Hopkins School of Nursing

  • Jennifer Kawi, PhD · University of Nevada, Las Vegas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2022-08-11
Completion
2022-08-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020470 on ClinicalTrials.gov